MT027 CAR-T cells

MT027 CAR-T cells is an allogeneic chimeric antigen receptor T-cell (CAR-T) therapy developed using CRISPR/Cas9 gene-editing technology. The therapy utilizes healthy donor T cells that are genetically modified to express a CAR targeting the tumor antigen B7-H3 (CD276), which is highly expressed in various solid tumors, including recurrent glioblastoma and high-grade glioma. As an "off-the-shelf" universal CAR-T product, MT027 addresses key limitations of autologous cell therapies such as lengthy preparation times and manufacturing challenges related to patient-derived T cells. The genetic modifications also aim to reduce the risk of graft-versus-host disease (GvHD) and host-versus-graft rejection (HvG). Preliminary clinical studies have demonstrated promising safety and efficacy in patients with relapsed or refractory high-grade gliomas and other advanced solid tumors. The product has received Orphan Drug Designation from the U.S. FDA for certain indications[2][3][6][8].

Other names

MT027 cells suspensionMT-027 cells suspensionMT 027 cells suspension